- Home
- CTNM vs HQL Comparison
CTNM vs HQL Comparison
Compare CTNM & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CTNM | HQL |
|---|---|---|
| Founded | 2009 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.0M | 490.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTNM | HQL |
|---|---|---|
| Price | $13.06 | $16.27 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 331.7K | 99.5K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $10.55 |
| 52 Week High | $16.33 | $17.80 |
Technical Indicators
Market Signals| Indicator | CTNM | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 47.79 |
| Support Level | $10.17 | $15.66 |
| Resistance Level | $13.18 | $17.40 |
| Average True Range (ATR) | 1.07 | 0.35 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 42.15 | 49.05 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.